Lung cancer is the leading cause of cancer deaths worldwide with non small-cell lung cancer (NSCLC) accounting for 80% of all lung cancers. Although activating mutations in genes of the RAS-MAPK pathway occur in up to 30% of all NSCLC, the cooperating genetic lesions that are required for lung cancer initiation and progression remain poorly understood. Here we identify a role for the cell polarity regulator Scribble (Scrib) in NSCLC. A survey of genomic databases reveals deregulation of SCRIB in human lung cancer and we show that Scrib þ / À mutant mice develop lung cancer by 540 days with a penetrance of 43%. To model NSCLC development in vivo, we used the extensively characterized LSL-KRas G12D murine model of NSCLC. We show that loss of Scrib and activated oncogenic KRas cooperate in vivo, resulting in more aggressive lung tumors, likely due to a synergistic elevation in RAS-MAPK signaling. Finally, we provide data consistent with immune infiltration having an important role in the acceleration of tumorigenesis in KRas G12D lung tumors following Scrib loss.
INTRODUCTION
Lung cancer is divided into two major histopathological subtypes: non small-cell lung cancer (NSCLC) and small-cell lung cancer, which account for 80 and 20% of all lung carcinomas, respectively. 1 Adenocarcinomas are the predominant subclass of NSCLC and are histologically heterogeneous. Consistent with other cancer types, lung adenocarcinoma develops as a series of morphologically distinct lesions, beginning with hyperplasia progressing to carcinoma and then invasive adenocarcinomas. 2 This suggests that as with other cancers, it is the accumulation of genetic events, such as activating oncogenes, inactivation of tumor suppressor genes as well as epigenetic alterations that contributes to drive lung tumor progression. For example, loss of tumor suppressors such as p53, p16 INK4A and LKB1 have been shown to cooperate with activation of the oncogene KRas to promote lung tumorigenesis. [3] [4] [5] With more people dying from lung cancer than any other type of cancer and the 5-year survival rate in the United States only increasing from 12.7 to 16.8% between 1984 to 2004 (SEER (Surveillance, Epidemiology, and End Results) Program, National Cancer Institute), there is an urgent need for further research to understand the molecular events that contribute to lung tumorigenesis. Scribble (Scrib) was originally identified as a neoplastic tumor suppressor in Drosophila melanogaster, with loss of function disrupting apico-basal polarity, junctional integrity and inducing inappropriate proliferation and tissue overgrowth. 6 Scrib is a membrane-associated LAP (LRR, Leucine Rich Repeats, And PDZ, PSD95/DLG/ZO-1) protein and contains both LRR and PDZ domains. 7 Alterations in Scrib expression levels are observed in a variety of tumor types including breast, cervical and prostate. [8] [9] [10] [11] [12] [13] [14] Data from cell lines and primary tissue samples suggest that altered expression and/or mislocalization of cell polarity proteins play a causal role in tumorigenesis [15] [16] [17] and we recently reported that mislocalization of Scrib in human prostate cancer correlates with poor survival. 14 Although the molecular mechanisms behind Scrib function are not well understood, Scrib has been implicated in numerous cellular processes including proliferation, differentiation, apoptosis, stemcell maintenance, migration and vesicle trafficking. 18, 19 Studies in Drosophila have demonstrated that loss of Scrib cooperates with activated Ras to increase tumor growth and metastasis. 20, 21 This cooperative relationship is conserved in mammals as Scrib loss cooperates with activated RAS in the non-transformed human breast cell line MCF10A to promote invasion, and in the prostate to accelerate tumorigenesis in mice. 14, 22 Here we identify a role for Scrib in NSCLC. Scrib heterozygosity predisposes mice to lung adenomas (43% incidence) with many of the characteristics seen in human NSCLC lesions. Analyses of public databases reveal that SCRIB is deregulated in human lung cancer. We also demonstrate that Scrib can cooperate with oncogenic KRas in the murine lung as Scrib loss synergizes with KRas G12D to promote tumor progression. Our data suggest that this may occur through hyperactivation of the mitogen activated protein kinaseextracellular signal-regulated kinase (MAPK-ERK) signaling pathway and recruitment of macrophages to lung lesions.
RESULTS

SCRIB is deregulated in human lung cancers
Disruption of cell polarity is recognized as a hallmark of cancer and it was recently reported that deregulation of cell polarity regulators is associated with a number of epithelial cancers. [8] [9] [10] [11] [12] [13] [14] We have performed detailed assessment of public databases from the Sanger Institute (www.sanger.ac.uk), the cBioPortal for Cancer Genomics (http://www.cbioportal.org) and The Cancer Genome Atlas (TCGA) (http://cancergenome.nih.gov/) to specifically investigate the role of SCRIB in human cancers. The COSMIC (Catalogue of Somatic Mutations in Cancer) database shows that of all tissue types analyzed, lung cancer samples carry the second highest percentage of SCRIB somatic mutations, of which eight are predicted to alter function (Figures 1a and c) . Copy number analysis using the copy number variation analysis tool (CONAN) database shows loss of heterozygosity in a significant percentage of lung cancer samples (Figure 1b) . Data sourced from TCGA revealed SCRIB to be altered in 4.4% (8/182) (Broad, Cell 2012) and 24.3% (56/230) (TCGA, Provisional) of all lung adenocarcinoma samples analyzed (Figure 1c) . A total of 19.7% of all lung squamous cell carcinoma samples analyzed displayed alterations in SCRIB (35/178), with 7/178 somatic mutations identified (Figure 1c) . Fourteen out of 21 of all SCRIB somatic mutations identified are predicted to have functional impact (Figure 1c ). Forty-three percent (6/14) of these functional mutations reside within the leucine rich repeat domain of SCRIB and 36% within one of SCRIB's four PDZ domains (Figure 1c) . The leucine rich repeat domain is known to be important for interactions with Ras, and the PDZ domains are required for protein-protein interactions. 7 Taken together, these data indicate that SCRIB may be a key player in human lung tumorigenesis.
Aged Scrib heterozygous mice are predisposed to lung adenomas We recently reported that Scrib heterozygosity in mice is sufficient to drive prostate hyperplasia.
14 When aged to 540 days, these mice also developed lung adenomas with 43% incidence compared with 6% in wild-type counterparts (Figures 2a-c) . These tumors ranged from atypical adenomatous hyperplasia to focal grade 3 lesions. PCR analysis on genomic DNA isolated from microdissected tumors confirmed that the Scrib-knockout allele is present only in tumors from the Scrib þ / À mice (Figure 2d ). Furthermore, quantitative real-time PCR of complementary DNA made from whole lobes quantitatively revealed Scrib expression to be halved in heterozygous lung tissue, and complementary DNA from dissected tumors showed 56% reduction in Scrib expression (Figure 2f ). Immunostaining for Scrib in these tumors showed significant expression and correct localization of Scrib to the membrane suggesting that no loss of heterozygosity had occurred (Figure 2e ). These data indicate heterozygous loss of Scrib sensitizes mice to develop tumorigenic lung lesions, establishing a role for deregulation of Scrib in lung tumorigenesis in vivo.
Development of a Scrib
fl/fl KRas G12D murine lung cancer model
To determine a role for Scrib loss during lung tumor initiation and progression, we utilized a conditional Scrib-deficient mouse (Scrib fl/fl ), which on administration of intranasal Adenoviral Cre (AdCre) resulted in the transduction of a small percentage of pulmonary cells 23 and excision of exons 4-13 comprising the majority of the leucine rich repeat domain, essential for Scrib function.
14 By 20 weeks post-AdCre infection only a single mouse from the Scrib fl/fl cohort (1/17) developed a lung lesion, whereas no lesions were observed in the phenotypically similar wild-type controls (n ¼ 10), thus suggesting that Scrib alone does not contribute to lung cancer initiation.
Data from our laboratory have shown that loss of Scrib can cooperate with oncogenic activation of Ras to drive epithelial tumorigenesis both in vitro and in vivo. As one-third of NSCLC display mutations in the KRas isoform, we assessed the contribution of Scrib loss to KRas-induced lung tumorigenesis in an in vivo setting, by using the extensively characterized LSL-KRas G12D mouse model. 23 Figure S1) . Figure S2) , further implicating Scrib in lung tumorigenesis. The data described above show loss of Scrib accelerates KRas-driven lung tumorigenesis, giving rise to more advanced and higher-grade tumors.
We have shown that loss of one Scrib allele sensitizes mice to develop lung lesions by 540 days and demonstrate here by employing an AdCre approach to delete Scrib specifically in the epithelial cells of the lung, a cell intrinsic role for Scrib during KRasinduced lung tumorigenesis.
Scrib loss does not accelerate lung tumorigenesis via cell proliferation, survival or differentiation in KRas-driven lung tumors To investigate the mechanisms by which loss of Scrib causes more aggressive KRas-driven lung tumors, we analyzed several cellular processes frequently associated with increased malignancy. We concentrated on tumor progression at the early 6 weeks postAdCre infection and the later 20 weeks post-AdCre infection time points, during the advanced stage of disease. Proliferating cell nuclear antigen staining was used to detect proliferating cells in tumors from KRas G12D and Scrib fl/fl KRas G12D mice at both 6 and 20 weeks post-AdCre infection (Figure 4a(i) ). Blind scoring for proliferating cell nuclear antigen-positive cells at 20 weeks revealed that, although Scrib-depleted tumors overall had a significant 1.77-fold increase in proliferation compared with the KRas G12D tumors, when tumors of a similar grade were compared, no significant differences between the genotypes were observed (Figure 4a (ii)). Therefore, despite the more aggressive tumors seen in Scrib fl/fl KRas G12D mice having higher rates of proliferation, Scrib itself does not directly contribute to an increase in proliferation and thus proliferation is unlikely to a be a causative factor driving cooperation between Ras activation and Scrib loss.
Evasion of apoptosis is recognized as a hallmark of cancer, 25 Figure S3A) . This result is consistent with several studies in the literature that report residual or undetectable apoptosis in KRas KRas G12D mice at 6 and 20 weeks postAdCre induction were stained for the proliferation marker proliferating cell nuclear antigen (PCNA: a(i)). Quantification of PCNA staining is shown in a(ii). Tumors were scored indiscriminately across all tumor grades (graph on left) and specifically grades 2/3 from both KRas G12D and Scrib fl/fl KRas G12D genotypes (graph on right). Error bars represent s.e.m., (n ¼ 3 for each genotype, unpaired t-test). The percentage of PCNApositive cells was calculated by counting the total number of positive and negative cells in IHC stained lung lesions from 12 fields at Â 40 magnification per mouse. Fields were taken from at least five different tumors per mouse from three mice of each genotype. Scoring was performed blind for all genotypes. Any obvious infiltrating cells were excluded from the analysis. Scale bars, 50 mm. models of lung cancer. 26, 27 It appears that apoptotic evasion mechanisms are already activated in KRas-driven lung tumors making it difficult to assess if Scrib acts on the cell death pathway. However, given that there are no detectable differences between the genotypes, any involvement Scrib may have in regulating apoptosis is unlikely to be a driver of malignancy in this model.
The cell type of origin of lung lesions was next determined using CC10 and Sp-C antibodies as markers of Clara cells and type II alveolar cells, respectively. In serial sections from lungs of KRas G12D and Scrib fl/fl KRas G12D mice, tumor cells stain positive for Sp-C, whereas bronchiolar cells stain positive for CC10 (Supplementary Figure S3B) . This suggests that tumors from both genotypes arise from type II alveolar cells, although it must be noted that this is still a contentious area of lung cancer biology. 28 Regardless of the precise identity of the cell type of origin, the similar staining patterns observed in both KRas G12D and Scrib Figures S4A and B) suggesting that these tumors share many of the same characteristics as KRas G12D -driven tumors. Together these data suggest that Scrib loss may accelerate tumor progression in KRas G12D -driven tumors by enhancing the conversion to higher-grade tumors rather than through direct alterations of proliferation, survival or differentiation.
Scrib loss disrupts adherens junctions at the invasive front of KRasdriven lung tumors and enhances local invasion but not metastasis To determine whether Scrib deficiency in KRas-induced lung cancer contributes to tumor progression by increasing cell migration and/or invasion, we assessed whether adherens junction proteins were normally localized in lung lesions. Dissolution of adherens junctions commonly occurs through the downregulation or mislocalization of E-cadherin thus, to assess junctional integrity, lung sections from KRas Loss of E-cadherin expression at invasive fronts is known to be one of the first steps in tumor cell invasion and metastasis 29 and it is possible that in the latter stages b-catenin expression may also be disrupted in Scrib fl/fl KRas G12D tumors. It would be interesting to perform a time course of circulating tumor cells to more accurately determine how Scrib loss is altering the invasion process. Analysis of adherens junctions in Scrib þ / À lung tumors again mimicked our observations in KRas G12D -driven lung tumors (Supplementary Figures S4C(i) and C(ii) ).
Loss of tumor suppressors such as p53, p16 INK4A and LKB1 are sufficient to promote metastasis in KRas-driven lung tumors. 
KRas
G12D mice had developed multiple, large tumors and displayed labored breathing and signs of distress. Perhaps ageing mice beyond 20 weeks after infection with a reduced AdCre dose would decrease tumor number and increase survival time and result in further disruption to adherens junctions, and thus invasion and metastasis in this model. Taken together these data suggest that, although no metastasis was observed in our mouse models, cells at the periphery of high-grade Scrib fl/fl KRas G12D tumors display aberrant E-cadherin expression, suggestive of adherens junction disruption, which is likely to contribute to the aggressive phenotype observed.
Scrib loss hyperactivates MAPK-ERK signaling in KRas
G12D lung lesions Synergistic behavior between Scrib loss and activated oncogenes has been reported in vitro and in vivo. 14, 22, 30 We analyzed The heterogeneous nature of the LSL-KRas G12D model meant that the levels of pERK varied between tumors in all genotypes. To circumvent this issue, we quantified nuclear pERK across all tumors using MetaMorph software. Surprisingly, tumors of the highest grade did not correspond to increased pERK staining and there was no strong correlation between tumor grade and pERK expression. However, within each specific tumor grade the percentage of pERK staining was elevated in Scrib fl/fl KRas G12D tumors compared with their counterpart KRas G12D tumors (Figure 6b(ii) ).
By grouping the tumors according to the percentage of pERK staining irrespective of grade, we were able to further analyze pERK staining in our mouse models. Groups were assigned based on the percentage of pERK staining within the tumor: 1-10%, 11-30% or 31-50% (Figure 6b(iii) ). Sixty-nine percent of the tumors analyzed from KRas G12D mice were 1-10% positive compared with 26% from Scrib fl/fl KRas G12D mice (Po0.05). Twenty-seven percent of the tumors from KRas G12D mice were 11-30% positive compared with 46% from Scrib fl/fl KRas G12D mice (P ¼ 0.01) and only 4% of the tumors analyzed from KRas G12D mice were 31-50% positive compared with 28% from Scrib fl/fl KRas G12D mice (Po0.05). These data indicate that in KRas-driven lung lesions loss of Scrib promotes hyperactive MAPK-ERK signaling. As an increase in pERK staining is observed irrespective of tumor grade, but as a result of Scrib loss, it is unlikely that increased MAPK-ERK signaling is responsible for maintaining a malignant state but rather, it is likely to be involved during tumor initiation and progression. Scrib loss has been previously shown to promote hyperactive MAPK-ERK signaling, supporting the findings of this study. 14, 22 Scrib loss enhances stromal reactivity and inflammation in KRasdriven lung tumors To further elucidate the molecular mechanisms underlying increased MAPK-ERK signaling, increased tumor formation and progression in KRas-driven lung tumors upon Scrib loss, microarray analysis was carried out on microdissected tumors from the lungs of KRas G12D and Scrib Figure S6B(i) ), confirming loss of Scrib in these tumors. Validation from the gene lists was carried out and STRING analysis was applied to map protein interactions and relationships (http://string-db.org/) (Supplementary Figure S6A) . Many of the gene signatures identified by our analysis including cell signaling, cell adhesion and cell cycle had already been examined as described above. However, the microarray analysis also showed differences in extracellular matrix remodeling and microenvironment-related pathways. Published observations indicate that high-grade tumors display a stromal reaction, which can be used as a measure of highly aggressive epithelial tumors. Therefore, we assessed the level of stromal reaction by staining for collagen using Massons Trichrome stain in our mouse models. influencing cancer outcome. 31, 32 Consistent with previous reports, 33 staining with the F4/80 marker revealed macrophage infiltration in the KRas-driven lung lesions at 6 and 20 weeks postAdCre infection (Figure 7b ). Scrib depletion in KRas-induced lung tumors resulted in an increase in the number of infiltrating macrophages compared with KRas G12D tumors (Figure 7b ). Tumorassociated macrophages have been proposed to contribute to tumor promoting activities. [34] [35] [36] Our previous in vitro work revealed that Scrib suppressed Ras-induced activation and expression of pro-inflammatory cytokines such as interleukin-6 (IL)-6 and IL-8. 22 Interestingly, in the current study, many immune genes including the cytokine receptor-like factor 1, an IL-6 family member, shown to be important in human inflammatory lung disease, 37 were downregulated upon Scrib loss. In addition, genes of the lymphocyte antigen 6 complex (Ly6) were identified in the microarray analysis as upregulated genes upon Scrib loss, further supporting a role for the immune system to help drive its effects (Supplementary Tables 1 and 2 and Supplementary Figures S6B(ii) and (iii)). Future work will delineate the mechanisms by which loss of Scrib impacts on the immune system to promote tumorigenesis in KRas-driven lung tumors.
DISCUSSION
In this study, we have demonstrated that Scrib deregulation may modulate human lung tumorigenesis. We have used a conditional transgenic approach to show that Scrib loss cooperates with oncogenic KRas to promote lung tumorigenesis and enhances the invasive potential of lung tumors, as seen with mammary cells grown in three-dimensional organotypic cultures and prostate cancer in vivo. 14, 22, 24 An increase in tumor burden, number and grade of lung lesions is observed in Scrib fl/fl KRas G12D mice compared with KRas G12D mice at both early and late time points. This demonstrates that Scrib loss of function can facilitate tumor progression in KRas-induced lung tumors. However, Scrib deficiency alone was insufficient to initiate lung tumorigenesis at 6, 12 and 20 weeks post-AdCre infection, but does sensitize mice to lung tumorigenesis during ageing when an accumulation of additional genetic mutations can occur. Despite the aggressive nature of the tumors seen in the Scrib fl/fl KRas G12D mice at the latter time point, no metastases were detected. Of note, mice that develop lymph node and other metastases in the KRas LSL-G12D lung model usually show reactive stroma around bronchial and blood vessels where the lung lymphatics run (Dr Roderick Bronson, personal communication). In this study, lungs displayed stromal proliferation around the periphery of the tumor with no stromal invasion into the lymphatics or veins, which is consistent with the lack of metastases observed.
Many studies have utilized the LSL-KRas G12D model originally described by Jackson et al. 24 including those showing that deregulation of proteins involved in polarity in the context of KRas G12D can enhance (LKB1 depletion) or suppress (Rac1 activation) lung tumorigenesis. 5, 38 Shaw et al. 39 have described a model using the LSL-KRas G12D allele, where loss of Sprouty2 leads to increased pERK in tumors. Sprouty proteins modulate receptor tyrosine kinase-induced pathways with Sprouty2 acting through inhibition of Raf. 40, 41 Scrib may function similarly, with overexpression of Scrib in human breast cancer cell lines shown to suppress the MAPK-ERK pathway including MEK and ERK phosphorylation. 42 In future studies, it will be important to determine whether the cooperation between Scrib and Ras is a phenomenon associated more generally with the deregulation of polarity and therefore whether other polarity proteins such as Dlg, Lgl and Crumbs3 similarly cooperate with Ras in tumorigenesis, or whether the cooperation between Scrib and Ras is a result of synergistic augmentation of MAPK-ERK signaling, which acts to accelerate tumor-related processes, or a combination of the two.
We and others 43 have consistently observed increased pERK signaling associated with Scrib depletion across various models. 14, 22 In keeping with this trend, we observe an increase in nuclear pERK in Scrib fl/fl KRas G12D lung lesions compared with single mutants. Aberrant MAPK-ERK signaling is considered to have a crucial role in cancer and is associated with poor prognosis. [44] [45] [46] [47] Despite extensive investigation into MAPK-ERK signaling in transformation, very little is known about how the level of MAPK-ERK activity contributes to the malignancy of an individual tumor. In this study, we found that loss of Scrib resulted in increased MAPK-ERK activity across all tumor grades (Figure 6b) . Although lung lesions arising in aged Scrib þ / À mice display hyperactive MAPK-ERK signaling (Supplementary Figure S4D) , the tumors arise only after a long latency. This, in combination with the observation that even at the advanced stage of 20 weeks postAdCre, very few Scrib fl/fl develop lung lesions (1/17) indicating that loss of Scrib alone is insufficient to increase MAPK-ERK signaling to levels required for tumor initiation. We speculate that elevated pERK expression upon Scrib depletion sensitizes cells to transformation and in the presence of additional mutations can facilitate progression.
Hyperactive MAPK-ERK signaling has been associated with disruption of adherens junctions and promoting invasion and migration of tumor cells. Additionally, augmentation of the Ras-MAPK-ERK signaling cascade has been linked to changes in the immune response through upregulation of inflammatory cytokines including IL-6 and IL-8 as well as crosstalk with the transforming growth factor beta pathway. [48] [49] [50] Evidence for a critical role of the microenvironment in cancer progression has been growing and is now considered a hallmark of cancer. 51 Infiltrating immune cells stimulate proliferation of neoplastic cells by supplying various mitogenic growth stimuli including chemokines, ILs and growth factors as well as altering the extracellular matrix by expressing various proteolytic enzymes. 52 Taken together, we speculate that loss of Scrib in KRas-driven lung tumors results in accelerated disease progression and invasion through the combined effects of hyperactivated MAPK-ERK signaling, which sensitizes cells to the accumulation of additional mutations and disrupts adherens junctions thus priming tumor cells for invasion. These processes work together with the recruitment and activation of immune cells capable of modulating the tumor microenvironment allowing further disease progression.
In conclusion, we show that Scrib heterozygozity sensitizes mice to lung tumorigenesis and biallelic loss cooperates with oncogenic KRas to promote highly aggressive lung tumors. Our data strongly support previous work demonstrating that Scrib has a role in promoting cancer progression. Consequently, further molecular delineation of the mechanisms underlying this ability will provides insight into the novel roles of therapeutic intervention that prevent loss of cell polarity contributing to tumor progression. We have strengthened the link between Scrib and MAPK-ERK signaling in a tumor setting and provided evidence that Scrib depletion alters the tumor microenvironment and immune response. Furthermore, our studies indicate that Scrib deregulation may modulate human lung tumorigenesis. Future studies will be required to ascertain how Scrib is linked to oncogenic KRas signaling in the human lung setting and to dissect the specific role of Scrib in signaling and cell polarity in terms of lung cancer initiation and progression.
MATERIALS AND METHODS
Mouse strains
KRas-LSL-G12D (KRas G12D ) mice were originally generated in Tyler Jacks Laboratory (MIT-CCR, Cambridge, MA, USA) (described in Jackson et al.
24
). Conditional Scrib-knockout mice and Scrib fl/fl mice were designed and generated in our laboratory as described in.
14 All mice were maintained in a pathogen-free environment and all procedures complied with the National Health and Medical Research Council animal ethics guidelines.
AdCre recombinase preparation and administration KRas G12D mice were infected with Cre recombinase expressed in an Adenoviral AxCan vector (referred to as AdCre) via intranasal inhalation (described 23 ). AdCre was obtained from the Baker Heart Institute (Melbourne, Victoria, Australia). Briefly, mice were injected with ketamine/xylene while anaesthetized AdCre was administered intranasally at a single dose of 2.5 Â 10 7 pfu/mouse in 62.5 ml/mouse Dulbecco's Modified Eagle medium containing 5.8 mM CaCl 2 . Following AdCre infection, mice were housed in a viral room and monitored for signs of distress or ill health. Mice were culled at 6, 12 and 20 weeks for further analysis.
Tissue preparations
The left lung lobe of mice killed at 20 weeks following AdCre delivery was removed and tumors were microdissected or the lobe was left whole and snap frozen. Whole lungs from mice killed 6 and 12 weeks post-AdCre infection and the right lobes of mice 20 weeks following AdCre delivery were fixed inflated with 10% formalin. All soft tissues were harvested and fixed in 10% formalin overnight at 4 1C before cassetting for histological analysis.
Tumor grading and quantification of tumor burden, number and size Pathological analysis and grading was based on a system described in 23 . Grading was carried out blindly on hematoxylin and eosin (H&E) stained slides by a veterinary pathologist. Tumor burden, tumor number and tumor area were determined by imaging H&E stained sections on a BX51 microscope, Â 1.25 objective (Olympus Corp., Shinjuku-ku, Tokyo, Japan) and calculated using MetaMorph 6.3 software (Molecular Devices Corp., Sunnyvale, CA, USA). Tumor area was manually measured and expressed as a percentage of total lung area to determine tumor burden.
Isolation of protein, RNA and genomic DNA from lung tumors Microdissected tumor samples were homogenized in lysis buffer for two pulses of 40 s at 6 m/s (MP Biomedicals, Santa Ana, CA, USA). Protein, RNA and genomic DNA were concurrently isolated from single tumor samples using the AllPrep DNA/RNA/Protein mini kit (Qiagen, #80004) according to the manufacturer's instructions.
Detection of the recombined KRas G12D allele Genomic DNA isolated from microdissected lung tumors was used in a PCR protocol obtained from the Tyler Jack's laboratory with primers designed to detect the presence of the wild-type KRas allele (622 bp), the unrecombined Lox-Stop-Lox cassette (500 bp) and the recombined KRas G12D allele (650 bp) (see Supplementary Methods for primer sequences).
Quantitative Real-Time PCR Complementary DNA samples were amplified in triplicate reactions using the SYBR Green dye detection method (Applied Biosystems, Foster City, CA, USA) as per manufacturer's instructions. Primers were designed over exon-exon boundaries and all samples were normalized to GAPDH control. Fold change between samples was calculated using the comparative C(T) method (see Supplementary Methods for primer sequences).
Antibodies, immunostaining and immunoblotting
For all immunohistochemical staining analysis, at least three sections from different mice were stained for any given genotype. Four micrometer paraffin wax sections were stained with H&E, Massons Trichrome stain or immunostained using the following antibodies: proliferating cell nuclear antigen 1:100, b-catenin 1:500, E-cadherin 1:100, CCP/CC10 1:1500, pERK1/ 2 1:100, Cleaved Caspase- Immunoblotting was carried out using protein lysates from KRas G12D and Scrib fl/fl KRas G12D microdissected tumor samples and whole wild-type lung lobes (n ¼ at least three for each genotype) and probed using anti-Scrib Quantification of pERK staining H&E stained lung sections from KRas G12D and Scrib fl/fl KRas G12D mice 20 weeks post-AdCre induction were matched to corresponding serial immunohistochemical staining lung sections stained for pERK, and images were taken using a Â 1.25 objective. Grades were assigned to tumors based on pathology analysis of H&E slides. An automated threshold was set using MetaMorph 6.3 software to identify regions of positive pERK staining. The tumor area was measured manually and the percentage of threshold area within the tumor was quantified to give a percentage of positive pERK staining (equivalent to hyperactivated MAPK-ERK signaling) per tumor. The tumor grade was recorded with the percentage.
Small animal imaging
PET imaging: mice were imaged as previously described in. 53 Briefly, mice were fasted for 3 h before being anesthetized with isoflurane and injected intravenously with 14.8 MBq 18 F-fluorodeoxyglucose. Anesthesia was maintained for a further 15 min before animals were allowed to recover. Ninety minutes following the tracer injection, mice were again anesthetized and imaged for 10 min on a Philips Mosaic small animal PET scanner. Images were reconstructed using a three-dimensional RAMLA (row action maximum likelihood algorithm) algorithm. Computed tomography imaging: following PET scanning the mice were euthanized under anesthesia before being computed tomography-imaged on a Discovery STE8 PET/computed tomography (GE Healthcare, Barrington, IL, USA). Images were analyzed and three-dimensional rendered using TrueD software (Siemens, Germany).
Microarray
Microarray experiments using RNA isolated from lung tumors of KRas
G12D
and Scrib fl/fl KRas G12D mice were performed using the GeneChip Mouse Gene 1.0 ST Array kit (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's instructions. Quality control metrics were carried out using Expression Console software (Affymetrix) and Partek software (Partek Incorporated, St Louis, MO, USA). Gene lists were generated using the Tukey's biweight 1 step summarization method (Partek Incorporated). Pathway and gene ontology analyses were applied using STRING software (http://string-db.org/).
